Published in J Neurol Neurosurg Psychiatry on June 01, 2004
Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A (2006) 1.96
Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res (2010) 1.76
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res (2009) 1.34
Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol (2009) 1.21
PTPmu suppresses glioma cell migration and dispersal. Neuro Oncol (2009) 1.12
Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). EMBO J (2007) 1.10
Astrocytes reverted to a neural progenitor-like state with transforming growth factor alpha are sensitized to cancerous transformation. Stem Cells (2009) 1.01
'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. J Neurooncol (2009) 1.01
The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol (2011) 1.00
Medulloblastoma: atypical CT and MRI findings in children. Pediatr Radiol (2010) 0.99
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis (2007) 0.94
A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer (2009) 0.92
Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res (2010) 0.88
Somatic alterations in brain tumors. Oncol Rep (2008) 0.85
Molecular mechanism of cytotoxicity induced by Hsp90-targeted Antp-TPR hybrid peptide in glioblastoma cells. Mol Cancer (2012) 0.83
The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med (2010) 0.83
Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene (2009) 0.82
RAD51 can inhibit PDGF-B-induced gliomagenesis and genomic instability. Neuro Oncol (2011) 0.82
A structural basis for cellular senescence. Aging (Albany NY) (2009) 0.82
Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma? FEBS Open Bio (2013) 0.77
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. J Cancer (2011) 0.77
FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme. Cell Mol Neurobiol (2009) 0.76
Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades. J Histochem Cytochem (2016) 0.75
Apoptosis in glioma-bearing rats after neural stem cell transplantation. Neural Regen Res (2013) 0.75
Prolactinoma associated with an ependymoma in the fourth ventricle: A case report and review of the literature. Oncol Lett (2015) 0.75
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev (2003) 8.00
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
The molecular basis of Turcot's syndrome. N Engl J Med (1995) 6.65
Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 6.58
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 6.29
Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A (1992) 5.53
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98
Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet (2001) 4.48
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev (2000) 4.24
Mutations in SUFU predispose to medulloblastoma. Nat Genet (2002) 3.78
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A (1990) 3.70
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol (1994) 3.66
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res (1998) 3.15
Targeted molecular therapy of GBM. Brain Pathol (2003) 3.02
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell (2001) 2.89
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene (1996) 2.73
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res (1993) 2.65
Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci U S A (1998) 2.61
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev (2003) 2.55
Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res (1997) 2.45
Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res (1998) 2.41
Clonal genomic alterations in glioma malignancy stages. Cancer Res (1988) 2.39
Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol (1998) 2.32
Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci U S A (1989) 2.14
Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene (1996) 2.13
Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol (2003) 2.08
Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys (1993) 1.99
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A (1997) 1.76
Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res (2000) 1.74
The retinoblastoma tumor suppressor protein. Adv Cancer Res (1994) 1.72
Platelet-derived growth factor in human glioma. Glia (1995) 1.71
Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res (1997) 1.71
Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol (1993) 1.67
Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res (2001) 1.60
Alterations of the TP53 gene in human gliomas. Cancer Res (1994) 1.58
Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene (1994) 1.58
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol (2003) 1.57
Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res (1994) 1.51
Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res (1996) 1.50
PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet (2003) 1.46
MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res (2001) 1.46
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
p53 mutations in nonastrocytic human brain tumors. Cancer Res (1991) 1.42
Distinct methylation profiles of glioma subtypes. Int J Cancer (2003) 1.38
C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer (2000) 1.37
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol (1990) 1.35
Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res (2000) 1.35
Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res (1997) 1.31
Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet (1999) 1.29
Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet Cytogenet (1998) 1.27
Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol (1999) 1.27
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol (2001) 1.27
Treatment and survival of low-grade astrocytoma in adults--1977-1988. Neurosurgery (1992) 1.27
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol (1999) 1.26
Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol (2001) 1.26
Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer (2001) 1.23
Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene (1997) 1.23
Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet (1988) 1.22
Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg (2000) 1.21
Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (1997) 1.19
Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol (2000) 1.17
Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer (2000) 1.16
Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol (1996) 1.15
Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet (1999) 1.12
Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol (2002) 1.12
Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet (1997) 1.11
A cytogenetic study of 53 human gliomas. Cancer Genet Cytogenet (1989) 1.11
Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer (2001) 1.10
Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res (1992) 1.04
Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol (1999) 0.98
Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol (2001) 0.97
Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer (1994) 0.95
A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol (2002) 0.95
Identification by fluorescence of the G chromosome lost in human meningomas. Hereditas (1972) 0.94
Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer (1995) 0.94
Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Res (1995) 0.93
Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain. N Engl J Med (1989) 0.92
Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol (2000) 0.92
Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer (1996) 0.92
Intracranial meningioma--a population study of ten years. Acta Neurol Scand (1970) 0.91
Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Br J Cancer (2000) 0.90
PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol (2001) 0.89
Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer (2001) 0.89
Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neurooncol (1999) 0.89
A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology (1993) 0.89
Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. Acta Neuropathol (2001) 0.89
Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol (1998) 0.87
Optic chiasmatic-hypothalamic glioma. Brain Pathol (1997) 0.86